NASDAQ$BLLN
BillionToOne, Inc. · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
BillionToOne reported Q1 2026 with $108.4M revenue, net income of $18M, and diluted EPS of $0.34.
For the period ended 2026-03-31, BillionToOne reported $108.4M revenue. Revenue $108.4M (+84% YoY) on prenatal and oncology testing. Net income $18.0M vs $(4.0)M loss prior year; diluted EPS $0.34. Molecular diagnostics scaling across Northstar and Unity products. No quarterly EPS guidance; test volume and reimbursement trends discussed.
- Revenue $108.4M (+84% YoY) on prenatal and oncology testing.
- Net income $18.0M vs $(4.0)M loss prior year; diluted EPS $0.34.
- Molecular diagnostics scaling across Northstar and Unity products.
Headline financials
Revenue & EPS history
BillionToOne, Inc. · Revenue · Quarterly
$108M
Forward guidance
No quarterly EPS guidance; test volume and reimbursement trends discussed.
Tailwinds
- Sharp revenue growth with profitability inflection.
- Gross margin expansion potential.
- Expanding diagnostic menu.
Headwinds
- Reimbursement and payer policy risk.
- Competition in NIPT and oncology liquid biopsy.
- R&D and commercial spend rising with scale.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 2 quarterly earnings reports · overlaid with Q1 2026
-4.7%
Avg return
Earnings day
+2.5%
Avg return
5 days after
-0.6%
Avg return
30 days after
33%
1 / 3 earnings
Positive
+1.9%
Q1 2026
Best reaction
-10.7%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.9% | +32.5% | +21.5% | |
| Q4 2025 | -10.7% | -13.2% | -1.8% | |
| Q3 2025 | -5.3% | -11.8% | -21.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro